Swixx BioPharma
PrivateLast Round
Buyout/LBO
Dec 15, 2025
Est. Valuation
$1.76B
Total Funding Raised
$78.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Swixx BioPharma is a healthcare services company that operates as a commercialization platform for biopharmaceutical, OTC, and medical device companies in markets where they choose not to have a direct presence.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Pharma Supply Chain, Compliance, Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Swixx BioPharma Comparables
Compare Swixx BioPharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GENESIS Pharma | 84% | |
| SALUS, Ljubljana, d.d. | 82% | |
| EVERSANA | 77% |
Swixx BioPharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Buyout/LBO | Dec 15, 2025 | ||||
| Private Equity | May 20, 2021 |
Key People
Founding team and executive leadership
Swixx BioPharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Buyout/LBO |
| HBM Healthcare Investments | Seed, Private Equity, Buyout/LBO |
| Mérieux Equity Partners | Buyout/LBO, Private Equity |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 25, 2026
Monthly visitors increased 37% MoM.
- Dec 15, 2025
Closed at $1.76B post-money valuation with SK Capital Partners leading.
Swixx BioPharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access